Amarin, Neopharm enter commercialization agreement for VAZKEPA

Amarin Corporation and Neopharm Israel announced that the two companies have entered into an exclusive marketing and commercialization agreement for VAZKEPA in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority. VAZKEPA capsules are the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid. The agreement follows Israel’s Ministry of Health Pharmaceuticals Division granting regulatory approval to VAZKEPA. The MOH issued its approval of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides and either established cardiovascular disease or diabetes and at least one other cardiovascular risk factor. Under the terms of the agreement with Neopharm, Amarin has appointed Neopharm as its sole and exclusive distributor of VAZKEPA in the territory to import, register, distribute and commercialize the product, in order to ensure access to patients. Amarin grants Neopharm the right to hold under its own name the Regulatory Approvals and Regulatory filings as the Marketing Authorization Holder for VAZKEPA in this territory. Amarin will be responsible for supplying finished product to Neopharm at a transfer price paid to Amarin.